AbCellera Biologics Inc. Operating Expenses
AbCellera Biologics Inc. (ABCL) reported Operating Expenses of $66.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- AbCellera Biologics Inc. operating expenses for the quarter ending 2026-06-30 was $66.83M, a 0.24% increase year-over-year.
- AbCellera Biologics Inc. operating expenses for the quarter ending 2026-03-31 was $65.83M, a 1.59% decline year-over-year.
- AbCellera Biologics Inc. operating expenses for the quarter ending 2025-12-31 was $73.44M, a 5.62% decline year-over-year.
- AbCellera Biologics Inc. operating expenses for the quarter ending 2025-09-30 was $85.23M, a 14.91% decline year-over-year.
- AbCellera Biologics Inc. operating expenses for fiscal 2025 was $292.23M, a 14.95% decline from fiscal 2024.
- AbCellera Biologics Inc. operating expenses for fiscal 2024 was $343.60M, a 24.84% increase from fiscal 2023.
- AbCellera Biologics Inc. operating expenses for fiscal 2023 was $275.23M, a 2.35% increase from fiscal 2022.
- AbCellera Biologics Inc. operating expenses for fiscal 2022 was $268.91M, a 57.45% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.83M 10-Q · filed 2026-08-05 | $132.66M 10-Q · filed 2026-08-05 | $206.10M derived: sum of 3 quarters · filed 2026-08-05 | $291.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $65.83M 10-Q · filed 2026-05-11 | $139.27M derived: sum of 2 quarters · filed 2026-05-11 | $224.50M derived: sum of 3 quarters · filed 2026-05-11 | $291.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $73.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $158.67M derived: sum of 2 quarters · filed 2026-02-24 | $225.34M derived: sum of 3 quarters · filed 2026-08-05 | $292.23M 10-K · filed 2026-02-24 |
| 2025-09-30 | $85.23M 10-Q · filed 2025-11-06 | $151.90M derived: sum of 2 quarters · filed 2026-08-05 | $218.80M 10-Q · filed 2025-11-06 | $296.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $66.67M 10-Q · filed 2026-08-05 | $133.57M 10-Q · filed 2026-08-05 | $211.37M derived: sum of 3 quarters · filed 2026-08-05 | $311.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $66.89M 10-Q · filed 2026-05-11 | $144.70M derived: sum of 2 quarters · filed 2026-05-11 | $244.87M derived: sum of 3 quarters · filed 2026-05-11 | $345.65M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $77.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $177.97M derived: sum of 2 quarters · filed 2026-02-24 | $278.75M derived: sum of 3 quarters · filed 2026-02-24 | $343.60M 10-K · filed 2026-02-24 |
| 2024-09-30 | $100.17M 10-Q · filed 2025-11-06 | $200.95M derived: sum of 2 quarters · filed 2025-11-06 | $265.79M 10-Q · filed 2025-11-06 | $341.03M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $100.78M 10-Q · filed 2025-08-07 | $165.63M 10-Q · filed 2025-08-07 | $240.86M derived: sum of 3 quarters · filed 2026-02-24 | $302.35M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $64.85M 10-Q · filed 2025-05-08 | $140.08M derived: sum of 2 quarters · filed 2026-02-24 | $201.57M derived: sum of 3 quarters · filed 2026-02-24 | $263.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $75.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $136.72M derived: sum of 2 quarters · filed 2026-02-24 | $198.17M derived: sum of 3 quarters · filed 2026-02-24 | $275.23M 10-K · filed 2026-02-24 |
| 2023-09-30 | $61.49M 10-Q · filed 2024-11-04 | $122.93M derived: sum of 2 quarters · filed 2024-11-04 | $200.00M 10-Q · filed 2024-11-04 | $259.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $61.45M 10-Q · filed 2024-08-06 | $138.51M 10-Q · filed 2024-08-06 | $197.83M derived: sum of 3 quarters · filed 2025-02-27 | $261.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $77.07M 10-Q · filed 2024-05-07 | $136.39M derived: sum of 2 quarters · filed 2025-02-27 | $200.04M derived: sum of 3 quarters · filed 2025-02-27 | $254.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $59.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $122.97M derived: sum of 2 quarters · filed 2025-02-27 | $177.28M derived: sum of 3 quarters · filed 2025-02-27 | $268.91M 10-K · filed 2025-02-27 |
| 2022-09-30 | $63.65M 10-Q · filed 2023-11-02 | $117.96M derived: sum of 2 quarters · filed 2023-11-02 | $209.59M 10-Q · filed 2023-11-02 | $267.37M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $54.31M 10-Q · filed 2023-08-03 | $145.94M 10-Q · filed 2023-08-03 | $203.72M derived: sum of 3 quarters · filed 2024-02-20 | $237.33M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $91.63M 10-Q · filed 2023-05-04 | $149.41M derived: sum of 2 quarters · filed 2024-02-20 | $183.01M derived: sum of 3 quarters · filed 2024-02-20 | $217.69M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $57.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $91.38M derived: sum of 2 quarters · filed 2024-02-20 | $126.06M derived: sum of 3 quarters · filed 2024-02-20 | $170.79M 10-K · filed 2024-02-20 |
| 2021-09-30 | $33.60M 10-Q · filed 2022-11-08 | $68.28M derived: sum of 2 quarters · filed 2022-11-08 | $113.01M 10-Q · filed 2022-11-08 | $160.08M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $34.68M 10-Q · filed 2022-08-09 | $79.41M 10-Q · filed 2022-08-09 | $126.48M derived: sum of 3 quarters · filed 2023-02-21 | $137.61M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $44.67M 10-Q · filed 2022-05-10 | $91.80M derived: sum of 2 quarters · filed 2023-02-21 | $102.93M derived: sum of 3 quarters · filed 2023-02-21 | $115.01M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $47.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $58.26M derived: sum of 2 quarters · filed 2023-02-21 | $70.34M derived: sum of 3 quarters · filed 2023-02-21 | $77.12M 10-K · filed 2023-02-21 |
| 2020-09-30 | $11.13M 10-Q · filed 2021-11-10 | $23.21M derived: sum of 2 quarters · filed 2021-11-10 | $29.99M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $12.08M 10-Q · filed 2021-08-13 | $18.86M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $6.78M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $15.73M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |